Sebi bans Wockhardt’s former executive from securities market for 6-month for insider trading
时间:2024-06-25 14:50:13 阅读(143)
Sebi has barred Yatendra Kumar, a former executive of Wockhardt Ltd, from the securities market for six months and directed him to disgorge losses of over Rs 14 lakh averted by flouting insider trading rules.
In addition, he has been restrained from buying, selling or dealing in the securities of Wockhardt Ltd for one year.
In its 50-page order on Monday, Sebi found that Kumar traded in the company’s shares when in possession of unpublished price-sensitive information (UPSI) regarding issuance of Form 483 by the US Food and Drug Administration (USFDA) to Wockhardt’s manufacturing facility at Waluj in Maharashtra.
Form 483 contains FDA’s observation in detail and is issued if USFDA finds objectionable conditions upon completion of inspection of facilities. The issuance of such a form is regarded as adverse observations. Unless rectified, it may ultimately lead to issuance or warning and import alert, which have financial implications for the concerned company.
Going by the order, the USFDA issued Form 483 to Wockhardt on March 22, 2013, which was price sensitive information, and the drug firm made the information public on April 15 of the same year by issuing a press release on its website. Thus, the period from March 22 – April 15, 2013 is considered a period of UPSI.
Kumar, who was holding the post of President Pharma Research, Global IP, Quality Assurance/Quality Control and Regulatory Affairs at Wockhardt, offloaded 6,841 shares between March 22, 2013 and April 14, 2013; and divested 1,041 shares between April 15, 2013, and July 31, 2013.
In his reply to Sebi, he accepted that he came to know about issuance of the form on March 22 itself.
By indulging in such trades, Kumar has averted loss of Rs 14.23 lakh and thereby violated insider trading rules and accordingly Sebi put several restrictions on him.
Last month, Wockhardt and its three promoter entities — Habil Khorakiwala, Murtaza Khorakiwala and Huzaifa Khorakiwala — settled with Sebi a case pertaining to alleged non-disclosure of adverse observations made by the USFDA about the company’ Waluj facility to the exchanges in 2013.
上一篇:75th Year of Independence Day of India- Beautiful pictures of ‘Tiranga Yatra’ from across nation
下一篇:World welcomes 2023! Sydney’s stunning fireworks to Delhi’s dazzling India Gate – See top pics
猜你喜欢
- Nifty may aim for 17850 level this week, India VIX falls to 17
- Nifty to extend gains or correction on cards- Check US stocks, Asian markets, FII activity, SGX Nifty, more
- Nifty to fall below 17650 or bulls to rage on Dalal Street- 7 things to know before share market opens
- Nifty may bounce to 17777 if it holds above 17450; watch Infosys, Kotak Bank, Titan, for action
- Nifty needs to negate formation of lower high pattern to head to 17700-17777; maximum call OI at 18000
- Nifty to climb above 18000 or bears to grip Dalal Street again- 7 things to know before share market opening bell
- FII, DII data- FPIs sold shares worth Rs 1877 cr, DIIs sold shares worth Rs 2 cr on August 2, Wednesday
- Adani Group stocks in lower circuit today- These scrips in downward spiral after MSCI review
- Adani Ports, PVR, Tata Power, UPL, Reliance, BPCL, Ami Lifesciences stocks in focus on 16 September 2022